共 136 条
[1]
Thrift AP(2017)Global epidemiology and burden of HCV infection and HCV-related disease Nat Rev Gastroenterol Hepatol 14 122-132
[2]
El-Serag HB(2012)Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study J Inf Dis 206 469-477
[3]
Kanwal F(2017)Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study Lancet Gastroenterol Hepatol 2 161-176
[4]
Lee MH(2016)Reversion of disease manifestations after HCV eradication J Hepatol 65 S95-S108
[5]
Yang HI(2017)Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review Ann Intern Med 166 637-648
[6]
Lu SN(2019)Effectiveness and safety of sofosbuvir/velpatasvir/voxiaprevir in patients with chronic hepatitis C previously treated with DAAs J Hepatol 71 666-672
[7]
Jen CL(2018)All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: the role of cirrhosis and comorbidities in treatment response PLoSONE 13 e0199941-312
[8]
You SL(2017)Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials Antivir Res 22 307-53
[9]
Wang LY(2017)Sofosbuvir/velpatasvir: the first pangenotypic direct-acting antiviral combination for hepatitis C Ann Pharmacother 51 44-1852
[10]
Blach S(2020)Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts Liver Int 40 1841-134